$29.04+0.21 (+0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Supernus (SUPN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~11.9%/yr (FY21→FY25), net margin 16.9%; free cash flow runs at −44% of net income. Check the accrual gap. Worth your attention in FY25: Capex step-up ($66.0M) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲4.3%
1,239.0
FY21→FY25CAGR +11.9%/yr
Net income ($M)▲2900.0%
210.0
one-off year: see footnoteCAGR +0.6%/yr
Free cash flow ($M)—
−93.0
capex stepped upCAGR —
Diluted EPS▲3180.0%
1.64
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Capex step-up
$66.0M
▲128% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
Returns vs FCF
n/m
$11.0M returned vs $−93.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
17¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 83.9% → 80.2%. Net margin 16.9% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,373.0 | 1,239.0 | 1,188.0 | 1,093.0 | 901.0 | 791.0 | ▲4.3% | +11.9% |
Cost of revenue | 208.0 | 246.0 | 231.0 | 174.0 | 151.0 | 127.0 | ▲6.5% | +18.0% |
Gross profit | 1,169.0 | 994.0 | 957.0 | 919.0 | 749.0 | 664.0 | ▲3.9% | +10.6% |
Research & development | 54.0 | 97.0 | 108.0 | 278.0 | 74.0 | 52.0 | ▼10.2% | +16.9% |
Selling, general & admin | 554.0 | 634.0 | 612.0 | 565.0 | 469.0 | 431.0 | ▲3.6% | +10.1% |
Total operating expenses | 608.0 | 731.0 | 919.0 | 1,073.0 | 831.0 | 483.0 | ▼20.5% | +10.9% |
Operating incomefeeds ROC rank | 558.0 | 262.0 | 38.0 | −152.0 | −81.0 | 213.0 | ▲589.5% | +5.3% |
Other income, net | −20.0 | −23.0 | −18.0 | 7.0 | −8.0 | −23.0 | — | — |
Pretax income | 538.0 | 239.0 | 20.0 | −145.0 | −89.0 | 190.0 | ▲1095.0% | +5.9% |
Income tax | 88.0 | 29.0 | 13.0 | −19.0 | −44.0 | −15.0 | ▲123.1% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 451.0 | 210.0 | 7.0 | −126.0 | −44.0 | 205.0 | ▲2900.0% | +0.6% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.58 | 1.64 | 0.05 | −0.92 | −0.32 | — | ▲3180.0% | — |
Diluted shares (mn) | 122.00 | 128.00 | 133.00 | 137.00 | 139.00 | — | ▼3.8% | −2.7% |
| Margins | ||||||||
Gross margin79th pct in Healthcare | 85.1% | 80.2% | 80.6% | 84.1% | 83.1% | 83.9% | ▼0.3pp | −3.7pp |
Operating margin | 40.6% | 21.1% | 3.2% | −13.9% | −9.0% | 26.9% | ▲17.9pp | −5.8pp |
Net margin96th pct in Healthcare | 32.8% | 16.9% | 0.6% | −11.5% | −4.9% | 25.9% | ▲16.4pp | −9.0pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −8% vs a 13% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 49% vs a 13% norm for this window, likely a one-time item; see the filing.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Supernus' revenue last fiscal year?
Supernus reported revenue of $1,239.0M in fiscal 2025, up 4.3% from fiscal 2024.
What was Supernus' net income?
Supernus reported net income of $210.0M in fiscal 2025, a net margin of 16.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

